Azithromycin in the treatment of COVID-19: a review

Introduction: SARS-CoV-2 is a novel virus that causes coronavirus disease-19 (COVID-19). Antiviral and immunomodulatory agents have been proposed as potential treatments. Azithromycin exhibits both properties and therefore may play a role. Areas covered: This article reviews the pharmacology, pharma...

Descripción completa

Detalles Bibliográficos
Autores: Echeverría Esnal, Daniel, Martín-Ontiyuelo, Clara, Navarrete Rouco, Maria Eugenia, De Antonio Cuscó, Marta, Ferrández, Olivia, Horcajada Gallego, Juan Pablo, Grau Cerrato, Santiago
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2021
País:España
Institución:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/47991
Acceso en línea:http://hdl.handle.net/10230/47991
http://dx.doi.org/10.1080/14787210.2020.1813024
Access Level:acceso abierto
Palabra clave:Azithromycin
COVID-19
SARS-CoV-2
Antivirals
Cytokine release syndrome
Immunomodulation
Pneumonia
id ES_3d54d3fdc8d87aebc84e076e17dc960f
oai_identifier_str oai:repositori.upf.edu:10230/47991
network_acronym_str ES
network_name_str España
repository_id_str
spelling Azithromycin in the treatment of COVID-19: a reviewEcheverría Esnal, DanielMartín-Ontiyuelo, ClaraNavarrete Rouco, Maria EugeniaDe Antonio Cuscó, MartaFerrández, OliviaHorcajada Gallego, Juan PabloGrau Cerrato, SantiagoAzithromycinCOVID-19SARS-CoV-2AntiviralsCytokine release syndromeImmunomodulationPneumoniaIntroduction: SARS-CoV-2 is a novel virus that causes coronavirus disease-19 (COVID-19). Antiviral and immunomodulatory agents have been proposed as potential treatments. Azithromycin exhibits both properties and therefore may play a role. Areas covered: This article reviews the pharmacology, pharmacokinetics, clinical efficacy, and safety of azithromycin in viral infections, with emphasis on COVID-19. A literature search of PUBMED was conducted on May 30th and updated on July 28th. Expert opinion: Azithromycin presents in vitro activity against SARS-CoV-2 and could act in different points of the viral cycle. Its immunomodulatory properties include the ability to downregulate cytokine production, maintain epithelial cell integrity or prevent lung fibrosis. Azithromycin use was associated with a reduction in mortality and ventilation days in other viral infections. These properties could be beneficial throughout the COVID-19. However, the evidence of its use is scarce and of low quality. Azithromycin has been assessed in retrospective observational studies mainly in combination with hydroxychloroquine, which has shown to provide no benefit. This macrolide presents a well-known safety profile. Upcoming clinical trials will determine the role of azithromycin in the COVID-19 (including the stage of the disease where it offers the greatest benefits and the effect of its combination with other drugs).Taylor & Francis20212021info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/47991http://dx.doi.org/10.1080/14787210.2020.1813024reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglés© This is an Accepted Manuscript of an article published by Taylor & Francis in Expert review of anti-infective therapy on Feb. 2021, available online: http://www.tandfonline.com/10.1080/14787210.2020.1813024info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/479912026-06-12T07:21:37Z
dc.title.none.fl_str_mv Azithromycin in the treatment of COVID-19: a review
title Azithromycin in the treatment of COVID-19: a review
spellingShingle Azithromycin in the treatment of COVID-19: a review
Echeverría Esnal, Daniel
Azithromycin
COVID-19
SARS-CoV-2
Antivirals
Cytokine release syndrome
Immunomodulation
Pneumonia
title_short Azithromycin in the treatment of COVID-19: a review
title_full Azithromycin in the treatment of COVID-19: a review
title_fullStr Azithromycin in the treatment of COVID-19: a review
title_full_unstemmed Azithromycin in the treatment of COVID-19: a review
title_sort Azithromycin in the treatment of COVID-19: a review
dc.creator.none.fl_str_mv Echeverría Esnal, Daniel
Martín-Ontiyuelo, Clara
Navarrete Rouco, Maria Eugenia
De Antonio Cuscó, Marta
Ferrández, Olivia
Horcajada Gallego, Juan Pablo
Grau Cerrato, Santiago
author Echeverría Esnal, Daniel
author_facet Echeverría Esnal, Daniel
Martín-Ontiyuelo, Clara
Navarrete Rouco, Maria Eugenia
De Antonio Cuscó, Marta
Ferrández, Olivia
Horcajada Gallego, Juan Pablo
Grau Cerrato, Santiago
author_role author
author2 Martín-Ontiyuelo, Clara
Navarrete Rouco, Maria Eugenia
De Antonio Cuscó, Marta
Ferrández, Olivia
Horcajada Gallego, Juan Pablo
Grau Cerrato, Santiago
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Azithromycin
COVID-19
SARS-CoV-2
Antivirals
Cytokine release syndrome
Immunomodulation
Pneumonia
topic Azithromycin
COVID-19
SARS-CoV-2
Antivirals
Cytokine release syndrome
Immunomodulation
Pneumonia
description Introduction: SARS-CoV-2 is a novel virus that causes coronavirus disease-19 (COVID-19). Antiviral and immunomodulatory agents have been proposed as potential treatments. Azithromycin exhibits both properties and therefore may play a role. Areas covered: This article reviews the pharmacology, pharmacokinetics, clinical efficacy, and safety of azithromycin in viral infections, with emphasis on COVID-19. A literature search of PUBMED was conducted on May 30th and updated on July 28th. Expert opinion: Azithromycin presents in vitro activity against SARS-CoV-2 and could act in different points of the viral cycle. Its immunomodulatory properties include the ability to downregulate cytokine production, maintain epithelial cell integrity or prevent lung fibrosis. Azithromycin use was associated with a reduction in mortality and ventilation days in other viral infections. These properties could be beneficial throughout the COVID-19. However, the evidence of its use is scarce and of low quality. Azithromycin has been assessed in retrospective observational studies mainly in combination with hydroxychloroquine, which has shown to provide no benefit. This macrolide presents a well-known safety profile. Upcoming clinical trials will determine the role of azithromycin in the COVID-19 (including the stage of the disease where it offers the greatest benefits and the effect of its combination with other drugs).
publishDate 2021
dc.date.none.fl_str_mv 2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/47991
http://dx.doi.org/10.1080/14787210.2020.1813024
url http://hdl.handle.net/10230/47991
http://dx.doi.org/10.1080/14787210.2020.1813024
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Taylor & Francis
publisher.none.fl_str_mv Taylor & Francis
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406433029652480
score 15.812429

Similares en LA Referencia